{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T21:54:41Z","timestamp":1793915681232,"version":"4.8.0"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T00:00:00Z","timestamp":1755648000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T00:00:00Z","timestamp":1755648000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Key Research Project of Sichuan Province","award":["2023YFS0199"],"award-info":[{"award-number":["2023YFS0199"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Med Res"],"DOI":"10.1186\/s40001-025-03057-6","type":"journal-article","created":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T02:44:04Z","timestamp":1755657844000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["The efficacy and safety of efgartigimod for refractory myasthenia gravis: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"30","author":[{"given":"Jia-Jun","family":"Cheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fu-Qiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhang-Yi","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,20]]},"reference":[{"issue":"1","key":"3057_CR1","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","volume":"5","author":"NE Gilhus","year":"2019","unstructured":"Gilhus NE, Tzartos S, Evoli A, Palace J, Burns TM, Verschuuren JJGM. Myasthenia gravis. Nat Rev Dis Primers. 2019;5(1):30. https:\/\/doi.org\/10.1038\/s41572-019-0079-y.","journal-title":"Nat Rev Dis Primers"},{"issue":"90","key":"3057_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1215\/00265667-4391153","volume":"2018","author":"SJ Jordan","year":"2018","unstructured":"Jordan SJ. Jillian. Minn Rev. 2018;2018(90):7\u20138. https:\/\/doi.org\/10.1215\/00265667-4391153.","journal-title":"Minn Rev"},{"key":"3057_CR3","doi-asserted-by":"publisher","DOI":"10.1021\/acschemneuro.9b00041","author":"ML Paz","year":"2019","unstructured":"Paz ML, Barrantes FJ. Autoimmune attack of the neuromuscular junction in myasthenia gravis: nicotinic acetylcholine receptors and other targets. ACS Chem Neurosci. 2019. https:\/\/doi.org\/10.1021\/acschemneuro.9b00041.","journal-title":"ACS Chem Neurosci"},{"issue":"11","key":"3057_CR4","doi-asserted-by":"publisher","first-page":"2843","DOI":"10.1172\/JCI29894","volume":"116","author":"BM Conti-Fine","year":"2006","unstructured":"Conti-Fine BM, Milani M, Kaminski HJ. Myasthenia gravis: past, present, and future. J Clin Invest. 2006;116(11):2843\u201354. https:\/\/doi.org\/10.1172\/JCI29894.","journal-title":"J Clin Invest"},{"issue":"2","key":"3057_CR5","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s00401-023-02603-y","volume":"146","author":"MC Pham","year":"2023","unstructured":"Pham MC, Masi G, Patzina R, et al. Individual myasthenia gravis autoantibody clones can efficiently mediate multiple mechanisms of pathology. Acta Neuropathol. 2023;146(2):319\u201336. https:\/\/doi.org\/10.1007\/s00401-023-02603-y.","journal-title":"Acta Neuropathol"},{"issue":"2","key":"3057_CR6","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1002\/mus.25973","volume":"57","author":"JS Yi","year":"2018","unstructured":"Yi JS, Guptill JT, Stathopoulos P, Nowak RJ, O\u2019Connor KC. B cells in the pathophysiology of myasthenia gravis. Muscle Nerve. 2018;57(2):172\u201384. https:\/\/doi.org\/10.1002\/mus.25973.","journal-title":"Muscle Nerve"},{"key":"3057_CR7","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jaut.2016.11.005","volume":"77","author":"I Koneczny","year":"2017","unstructured":"Koneczny I, Stevens JAA, De Rosa A, et al. IgG4 autoantibodies against muscle-specific kinase undergo fab-arm exchange in myasthenia gravis patients. J Autoimmun. 2017;77:104\u201315. https:\/\/doi.org\/10.1016\/j.jaut.2016.11.005.","journal-title":"J Autoimmun"},{"issue":"2","key":"3057_CR8","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.cell.2008.10.002","volume":"135","author":"N Kim","year":"2008","unstructured":"Kim N, Stiegler AL, Cameron TO, et al. Lrp4 is a receptor for Agrin and forms a complex with MuSK. Cell. 2008;135(2):334\u201342. https:\/\/doi.org\/10.1016\/j.cell.2008.10.002.","journal-title":"Cell"},{"issue":"6","key":"3057_CR9","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.3390\/ijms19061677","volume":"19","author":"PM Rodr\u00edguez Cruz","year":"2018","unstructured":"Rodr\u00edguez Cruz PM, Palace J, Beeson D. The neuromuscular junction and wide heterogeneity of congenital myasthenic syndromes. Int J Mol Sci. 2018;19(6):1677. https:\/\/doi.org\/10.3390\/ijms19061677.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"3057_CR10","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.cbi.2012.08.020","volume":"203","author":"K Ohno","year":"2013","unstructured":"Ohno K, Ito M, Kawakami Y, Krejci E, Engel AG. Specific binding of collagen Q to the neuromuscular junction is exploited to cure congenital myasthenia and to explore bases of myasthenia gravis. Chem Biol Interact. 2013;203(1):335\u201340. https:\/\/doi.org\/10.1016\/j.cbi.2012.08.020.","journal-title":"Chem Biol Interact"},{"key":"3057_CR11","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1111\/j.1749-6632.1998.tb10972.x","volume":"841","author":"MA Agius","year":"1998","unstructured":"Agius MA, Zhu S, Kirvan CA, et al. Rapsyn antibodies in myasthenia gravis. Ann N Y Acad Sci. 1998;841:516\u201321. https:\/\/doi.org\/10.1111\/j.1749-6632.1998.tb10972.x.","journal-title":"Ann N Y Acad Sci."},{"issue":"10","key":"3057_CR12","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1016\/j.autrev.2014.08.039","volume":"13","author":"E Gallardo","year":"2014","unstructured":"Gallardo E, Mart\u00ednez-Hern\u00e1ndez E, Titulaer MJ, et al. Cortactin autoantibodies in myasthenia gravis. Autoimmun Rev. 2014;13(10):1003\u20137. https:\/\/doi.org\/10.1016\/j.autrev.2014.08.039.","journal-title":"Autoimmun Rev"},{"issue":"5","key":"3057_CR13","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/nrneurol.2016.44","volume":"12","author":"NE Gilhus","year":"2016","unstructured":"Gilhus NE, Skeie GO, Romi F, Lazaridis K, Zisimopoulou P, Tzartos S. Myasthenia gravis - autoantibody characteristics and their implications for therapy. Nat Rev Neurol. 2016;12(5):259\u201368. https:\/\/doi.org\/10.1038\/nrneurol.2016.44.","journal-title":"Nat Rev Neurol"},{"issue":"3","key":"3057_CR14","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/S1474-4422(18)30467-8","volume":"18","author":"S Berrih-Aknin","year":"2019","unstructured":"Berrih-Aknin S, Le Panse R. Thymectomy in myasthenia gravis: when, why, and how? Lancet Neurol. 2019;18(3):225\u20136. https:\/\/doi.org\/10.1016\/S1474-4422(18)30467-8.","journal-title":"Lancet Neurol"},{"issue":"4","key":"3057_CR15","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","volume":"87","author":"DB Sanders","year":"2016","unstructured":"Sanders DB, Wolfe GI, Benatar M, et al. International consensus guidance for management of myasthenia gravis: executive summary. Neurology. 2016;87(4):419\u201325. https:\/\/doi.org\/10.1212\/WNL.0000000000002790.","journal-title":"Neurology."},{"key":"3057_CR16","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.jns.2016.08.057","volume":"369","author":"L Gotterer","year":"2016","unstructured":"Gotterer L, Li Y. Maintenance immunosuppression in myasthenia gravis. J Neurol Sci. 2016;369:294\u2013302. https:\/\/doi.org\/10.1016\/j.jns.2016.08.057.","journal-title":"J Neurol Sci"},{"issue":"772","key":"3057_CR17","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1136\/pgmj.66.772.102","volume":"66","author":"V Fonseca","year":"1990","unstructured":"Fonseca V, Havard CW. Long term treatment of myasthenia gravis with azathioprine. Postgrad Med J. 1990;66(772):102\u20135. https:\/\/doi.org\/10.1136\/pgmj.66.772.102.","journal-title":"Postgrad Med J"},{"issue":"2","key":"3057_CR18","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1177\/1756285615571873","volume":"8","author":"JL Cruz","year":"2015","unstructured":"Cruz JL, Wolff ML, Vanderman AJ, Brown JN. The emerging role of tacrolimus in myasthenia gravis. Ther Adv Neurol Disord. 2015;8(2):92\u2013103. https:\/\/doi.org\/10.1177\/1756285615571873.","journal-title":"Ther Adv Neurol Disord"},{"issue":"4","key":"3057_CR19","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s40265-019-1065-0","volume":"79","author":"G Beecher","year":"2019","unstructured":"Beecher G, Putko BN, Wagner AN, Siddiqi ZA. Therapies directed against B-cells and downstream effectors in generalized autoimmune myasthenia gravis: current status. Drugs. 2019;79(4):353\u201364. https:\/\/doi.org\/10.1007\/s40265-019-1065-0.","journal-title":"Drugs"},{"issue":"7","key":"3057_CR20","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1172\/JCI6968","volume":"104","author":"BL Dickinson","year":"1999","unstructured":"Dickinson BL, Badizadegan K, Wu Z, et al. Bidirectional FcRn-dependent IgG transport in a polarized human intestinal epithelial cell line. J Clin Invest. 1999;104(7):903\u201311. https:\/\/doi.org\/10.1172\/JCI6968.","journal-title":"J Clin Invest"},{"issue":"24","key":"3057_CR21","doi-asserted-by":"publisher","first-page":"9927","DOI":"10.1073\/pnas.1019037108","volume":"108","author":"K Baker","year":"2011","unstructured":"Baker K, Qiao SW, Kuo TT, et al. Neonatal Fc receptor for IgG (FcRn) regulates cross-presentation of IgG immune complexes by CD8-CD11b+ dendritic cells. Proc Natl Acad Sci U S A. 2011;108(24):9927\u201332. https:\/\/doi.org\/10.1073\/pnas.1019037108.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"3057_CR22","doi-asserted-by":"publisher","first-page":"3811","DOI":"10.4049\/jimmunol.181.6.3811","volume":"181","author":"P Bj\u00f6rck","year":"2008","unstructured":"Bj\u00f6rck P, Beilhack A, Herman EI, Negrin RS, Engleman EG. Plasmacytoid dendritic cells take up opsonized antigen leading to CD4+ and CD8+ T cell activation in vivo. J Immunol. 2008;181(6):3811\u20137. https:\/\/doi.org\/10.4049\/jimmunol.181.6.3811.","journal-title":"J Immunol"},{"key":"3057_CR23","doi-asserted-by":"publisher","first-page":"3052","DOI":"10.3389\/fimmu.2019.03052","volume":"10","author":"KL Gable","year":"2019","unstructured":"Gable KL, Guptill JT. Antagonism of the neonatal Fc receptor as an emerging treatment for Myasthenia Gravis. Front Immunol. 2019;10:3052. https:\/\/doi.org\/10.3389\/fimmu.2019.03052.","journal-title":"Front Immunol"},{"issue":"11","key":"3057_CR24","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.3390\/jcm10112235","volume":"10","author":"L Dresser","year":"2021","unstructured":"Dresser L, Wlodarski R, Rezania K, Soliven B. Myasthenia gravis: epidemiology, pathophysiology and clinical manifestations. J Clin Med. 2021;10(11):2235. https:\/\/doi.org\/10.3390\/jcm10112235.","journal-title":"J Clin Med"},{"issue":"51","key":"3057_CR25","doi-asserted-by":"publisher","first-page":"20783","DOI":"10.1073\/pnas.1313944110","volume":"110","author":"MG Huijbers","year":"2013","unstructured":"Huijbers MG, Zhang W, Klooster R, et al. MuSK IgG4 autoantibodies cause myasthenia gravis by inhibiting binding between MuSK and Lrp4. Proc Natl Acad Sci U S A. 2013;110(51):20783\u20138. https:\/\/doi.org\/10.1073\/pnas.1313944110.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"3057_CR26","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1038\/nbt1143","volume":"23","author":"C Vaccaro","year":"2005","unstructured":"Vaccaro C, Zhou J, Ober RJ, Ward ES. Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels. Nat Biotechnol. 2005;23(10):1283\u20138. https:\/\/doi.org\/10.1038\/nbt1143.","journal-title":"Nat Biotechnol"},{"issue":"10","key":"3057_CR27","doi-asserted-by":"publisher","first-page":"4372","DOI":"10.1172\/JCI97911","volume":"128","author":"P Ulrichts","year":"2018","unstructured":"Ulrichts P, Guglietta A, Dreier T, et al. Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans. J Clin Invest. 2018;128(10):4372\u201386. https:\/\/doi.org\/10.1172\/JCI97911.","journal-title":"J Clin Invest"},{"issue":"3","key":"3057_CR28","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s40265-022-01678-3","volume":"82","author":"YA Heo","year":"2022","unstructured":"Heo YA. Efgartigimod: first approval. Drugs. 2022;82(3):341\u20138. https:\/\/doi.org\/10.1007\/s40265-022-01678-3.","journal-title":"Drugs"},{"issue":"7","key":"3057_CR29","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","volume":"20","author":"JF Howard","year":"2021","unstructured":"Howard JF, Bril V, Vu T, et al. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2021;20(7):526\u201336. https:\/\/doi.org\/10.1016\/S1474-4422(21)00159-9.","journal-title":"Lancet Neurol"},{"key":"3057_CR30","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000007600","author":"V Bril","year":"2019","unstructured":"Bril V, Burns TM, Mantegazza R, et al. Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis. Neurology. 2019. https:\/\/doi.org\/10.1212\/WNL.0000000000007600.","journal-title":"Neurology."},{"key":"3057_CR31","doi-asserted-by":"publisher","first-page":"b2700","DOI":"10.1136\/bmj.b2700","volume":"339","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700. https:\/\/doi.org\/10.1136\/bmj.b2700.","journal-title":"BMJ"},{"issue":"7","key":"3057_CR32","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1212\/wnl.52.7.1487","volume":"52","author":"GI Wolfe","year":"1999","unstructured":"Wolfe GI, Herbelin L, Nations SP, Foster B, Bryan WW, Barohn RJ. Myasthenia gravis activities of daily living profile. Neurology. 1999;52(7):1487\u20139. https:\/\/doi.org\/10.1212\/wnl.52.7.1487.","journal-title":"Neurology."},{"issue":"9","key":"3057_CR33","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1046\/j.1445-2197.2003.02748.x","volume":"73","author":"K Slim","year":"2003","unstructured":"Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J. Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg. 2003;73(9):712\u20136. https:\/\/doi.org\/10.1046\/j.1445-2197.2003.02748.x.","journal-title":"ANZ J Surg"},{"key":"3057_CR34","doi-asserted-by":"publisher","first-page":"i4919","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JA Sterne","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919. https:\/\/doi.org\/10.1136\/bmj.i4919.","journal-title":"BMJ."},{"issue":"8","key":"3057_CR35","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1002\/acn3.52142","volume":"11","author":"S Luo","year":"2024","unstructured":"Luo S, Jiang Q, Zeng W, et al. Efgartigimod for generalized myasthenia gravis: a multicenter real-world cohort study in China. Ann Clin Transl Neurol. 2024;11(8):2212\u201321. https:\/\/doi.org\/10.1002\/acn3.52142.","journal-title":"Ann Clin Transl Neurol"},{"key":"3057_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1418503","author":"J Song","year":"2024","unstructured":"Song J, Wang H, Huan X, et al. Efgartigimod as a promising add-on therapy for myasthenic crisis: a prospective case series. Front Immunol. 2024. https:\/\/doi.org\/10.3389\/fimmu.2024.1418503.","journal-title":"Front Immunol"},{"issue":"4","key":"3057_CR37","doi-asserted-by":"publisher","first-page":"e16189","DOI":"10.1111\/ene.16189","volume":"31","author":"R Frangiamore","year":"2024","unstructured":"Frangiamore R, Rinaldi E, Vanoli F, et al. Efgartigimod in generalized myasthenia gravis: a real-life experience at a national reference center. Eur J Neurol. 2024;31(4):e16189. https:\/\/doi.org\/10.1111\/ene.16189.","journal-title":"Eur J Neurol"},{"issue":"3","key":"3057_CR38","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1002\/mus.28184","volume":"70","author":"L Remijn-Nelissen","year":"2024","unstructured":"Remijn-Nelissen L, Tannemaat MR, Ruiter AM, Campman YJM, Verschuuren JJGM. Efgartigimod in refractory autoimmune myasthenia gravis. Muscle Nerve. 2024;70(3):325\u201332. https:\/\/doi.org\/10.1002\/mus.28184.","journal-title":"Muscle Nerve"},{"key":"3057_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2024.1407418","author":"P Wang","year":"2024","unstructured":"Wang P, Zhang B, Yin J, et al. Prospective cohort study evaluating efficacy and safety of efgartigimod in Chinese generalized myasthenia gravis patients. Front Neurol. 2024. https:\/\/doi.org\/10.3389\/fneur.2024.1407418.","journal-title":"Front Neurol"},{"issue":"6","key":"3057_CR40","doi-asserted-by":"publisher","first-page":"3462","DOI":"10.1007\/s00415-024-12293-5","volume":"271","author":"L Fuchs","year":"2024","unstructured":"Fuchs L, Shelly S, Vigiser I, et al. Real-world experience with efgartigimod in patients with myasthenia gravis. J Neurol. 2024;271(6):3462\u201370. https:\/\/doi.org\/10.1007\/s00415-024-12293-5.","journal-title":"J Neurol"},{"key":"3057_CR41","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.nmd.2024.04.005","volume":"39","author":"K Horiuchi","year":"2024","unstructured":"Horiuchi K, Nakamura S, Yamada K, Inoue T, Oiwa K. Retrospective analysis of efgartigimod use in patients with double-seronegative generalized myasthenia gravis: a case series. Neuromuscul Disord. 2024;39:37\u201341. https:\/\/doi.org\/10.1016\/j.nmd.2024.04.005.","journal-title":"Neuromuscul Disord"},{"issue":"5","key":"3057_CR42","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1002\/mus.27974","volume":"68","author":"N Katyal","year":"2023","unstructured":"Katyal N, Halldorsdottir K, Govindarajan R, et al. Safety and outcomes with efgartigimod use for acetylcholine receptor-positive generalized myasthenia gravis in clinical practice. Muscle Nerve. 2023;68(5):762\u20136. https:\/\/doi.org\/10.1002\/mus.27974.","journal-title":"Muscle Nerve"},{"key":"3057_CR43","doi-asserted-by":"publisher","first-page":"886625","DOI":"10.3389\/fneur.2022.886625","volume":"13","author":"HJ Kaminski","year":"2022","unstructured":"Kaminski HJ, Denk J. Corticosteroid treatment-resistance in myasthenia gravis. Front Neurol. 2022;13:886625. https:\/\/doi.org\/10.3389\/fneur.2022.886625.","journal-title":"Front Neurol"},{"issue":"6","key":"3057_CR44","doi-asserted-by":"publisher","first-page":"e16367","DOI":"10.1016\/j.heliyon.2023.e16367","volume":"9","author":"G Antonini","year":"2023","unstructured":"Antonini G, Habetswallner F, Inghilleri M, et al. Real world study on prevalence, treatment and economic burden of myasthenia gravis in Italy. Heliyon. 2023;9(6):e16367. https:\/\/doi.org\/10.1016\/j.heliyon.2023.e16367.","journal-title":"Heliyon"},{"key":"3057_CR45","doi-asserted-by":"crossref","unstructured":"Binks S, Vincent A, Palace J. Myasthenia gravis: a clinical-immunological update. J Neurol. 2016 Apr;263(4):826-34. doi: 10.1007\/s00415-015-7963-5. Epub 2015 Dec 24. PMID: 26705120; PMCID: PMC4826656.","DOI":"10.1007\/s00415-015-7963-5"},{"key":"3057_CR46","doi-asserted-by":"publisher","first-page":"1284444","DOI":"10.3389\/fneur.2023.1284444","volume":"14","author":"JF Howard","year":"2023","unstructured":"Howard JF, Bril V, Vu T, et al. Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT+): interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravis. Front Neurol. 2023;14:1284444. https:\/\/doi.org\/10.3389\/fneur.2023.1284444.","journal-title":"Front Neurol."},{"key":"3057_CR47","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1212757","author":"AG Vakrakou","year":"2023","unstructured":"Vakrakou AG, Karachaliou E, Chroni E, et al. Immunotherapies in MuSK-positive myasthenia gravis; an IgG4 antibody-mediated disease. Front Immunol. 2023. https:\/\/doi.org\/10.3389\/fimmu.2023.1212757.","journal-title":"Front Immunol"},{"issue":"10","key":"3057_CR48","doi-asserted-by":"publisher","first-page":"4372","DOI":"10.1172\/JCI97911","volume":"128","author":"P Ulrichts","year":"2018","unstructured":"Ulrichts P, Guglietta A, Dreier T, et al. Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans. J Clin Invest. 2018;128(10):4372\u201386. https:\/\/doi.org\/10.1172\/JCI97911.","journal-title":"J Clin Invest"},{"key":"3057_CR49","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1401972","author":"G Zhu","year":"2024","unstructured":"Zhu G, Ma Y, Zhou H, et al. Case report: Rapid clinical improvement in acute exacerbation of MuSK-MG with efgartigimod. Front Immunol. 2024. https:\/\/doi.org\/10.3389\/fimmu.2024.1401972.","journal-title":"Front Immunol"},{"key":"3057_CR50","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.nmd.2024.04.005","volume":"39","author":"K Horiuchi","year":"2024","unstructured":"Horiuchi K, Nakamura S, Yamada K, Inoue T, Oiwa K. Retrospective analysis of efgartigimod use in patients with double-seronegative generalized myasthenia gravis: a case series. Neuromuscul Disord. 2024;39:37\u201341. https:\/\/doi.org\/10.1016\/j.nmd.2024.04.005.","journal-title":"Neuromuscul Disord"},{"key":"3057_CR51","doi-asserted-by":"publisher","first-page":"115872","DOI":"10.1016\/j.bcp.2023.115872","volume":"218","author":"X Chen","year":"2023","unstructured":"Chen X, Qiu J, Gao Z, et al. Myasthenia gravis: molecular mechanisms and promising therapeutic strategies. Biochem Pharmacol. 2023;218:115872. https:\/\/doi.org\/10.1016\/j.bcp.2023.115872.","journal-title":"Biochem Pharmacol"},{"key":"3057_CR52","doi-asserted-by":"publisher","first-page":"105231","DOI":"10.1016\/j.ebiom.2024.105231","volume":"105","author":"C Nelke","year":"2024","unstructured":"Nelke C, Schroeter CB, Barman S, et al. Identification of disease phenotypes in acetylcholine receptor-antibody myasthenia gravis using proteomics-based consensus clustering. eBioMedicine. 2024;105:105231. https:\/\/doi.org\/10.1016\/j.ebiom.2024.105231.","journal-title":"eBioMedicine"},{"issue":"5","key":"3057_CR53","doi-asserted-by":"publisher","first-page":"102800","DOI":"10.1016\/j.autrev.2021.102800","volume":"20","author":"R Zhao","year":"2021","unstructured":"Zhao R, Luo S, Zhao C. The role of innate immunity in myasthenia gravis. Autoimmun Rev. 2021;20(5):102800. https:\/\/doi.org\/10.1016\/j.autrev.2021.102800.","journal-title":"Autoimmun Rev"},{"issue":"8","key":"3057_CR54","doi-asserted-by":"publisher","first-page":"2690","DOI":"10.1007\/s00415-020-10263-1","volume":"268","author":"S Sriwastava","year":"2021","unstructured":"Sriwastava S, Tandon M, Kataria S, Daimee M, Sultan S. New onset of ocular myasthenia gravis in a patient with COVID-19: a novel case report and literature review. J Neurol. 2021;268(8):2690\u20136. https:\/\/doi.org\/10.1007\/s00415-020-10263-1.","journal-title":"J Neurol"},{"issue":"9","key":"3057_CR55","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/j.autrev.2013.03.007","volume":"12","author":"A Marx","year":"2013","unstructured":"Marx A, Pfister F, Schalke B, Saruhan-Direskeneli G, Melms A, Str\u00f6bel P. The different roles of the thymus in the pathogenesis of the various myasthenia gravis subtypes. Autoimmun Rev. 2013;12(9):875\u201384. https:\/\/doi.org\/10.1016\/j.autrev.2013.03.007.","journal-title":"Autoimmun Rev"},{"issue":"4","key":"3057_CR56","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.4049\/jimmunol.167.4.1935","volume":"167","author":"GP Sims","year":"2001","unstructured":"Sims GP, Shiono H, Willcox N, Stott DI. Somatic hypermutation and selection of B cells in thymic germinal centers responding to acetylcholine receptor in myasthenia gravis. J Immunol Baltim Md 1950. 2001;167(4):1935\u201344. https:\/\/doi.org\/10.4049\/jimmunol.167.4.1935.","journal-title":"J Immunol Baltim Md 1950"},{"key":"3057_CR57","doi-asserted-by":"publisher","first-page":"686466","DOI":"10.3389\/fimmu.2021.686466","volume":"12","author":"C Zografou","year":"2021","unstructured":"Zografou C, Vakrakou AG, Stathopoulos P. Short- and long-lived autoantibody-secreting cells in autoimmune neurological disorders. Front Immunol. 2021;12:686466. https:\/\/doi.org\/10.3389\/fimmu.2021.686466.","journal-title":"Front Immunol"},{"key":"3057_CR58","doi-asserted-by":"publisher","unstructured":"Feferman T, Maiti PK, Berrih-Aknin S, Bismuth J, Bidault J, Fuchs S, Souroujon MC. Overexpression of IFN-induced protein 10 and its receptor CXCR3 in myasthenia gravis. J Immunol. 2005 May 1;174(9):5324-31. doi: 10.4049\/jimmunol.174.9.5324. PMID: 15843529. https:\/\/doi.org\/10.4049\/jimmunol.174.9.5324","DOI":"10.4049\/jimmunol.174.9.5324"},{"issue":"3","key":"3057_CR59","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1111\/cei.13546","volume":"203","author":"A Uzawa","year":"2021","unstructured":"Uzawa A, Kuwabara S, Suzuki S, et al. Roles of cytokines and T cells in the pathogenesis of myasthenia gravis. Clin Exp Immunol. 2021;203(3):366\u201374. https:\/\/doi.org\/10.1111\/cei.13546.","journal-title":"Clin Exp Immunol"},{"key":"3057_CR60","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens12060817","author":"Y Zhou","year":"2023","unstructured":"Zhou Y, Jiang S. Roles of FcRn in antigen-presenting cells during autoimmunity and a clinical evaluation of efgartigimod as an FcRn blocker. Pathogens. 2023. https:\/\/doi.org\/10.3390\/pathogens12060817.","journal-title":"Pathogens"},{"key":"3057_CR61","doi-asserted-by":"publisher","first-page":"112583","DOI":"10.1016\/j.intimp.2024.112583","volume":"138","author":"S Qian","year":"2024","unstructured":"Qian S, Zhang D, Yang Z, et al. The role of immunoglobulin transport receptor, neonatal Fc receptor in mucosal infection and immunity and therapeutic intervention. Int Immunopharmacol. 2024;138:112583. https:\/\/doi.org\/10.1016\/j.intimp.2024.112583.","journal-title":"Int Immunopharmacol"},{"issue":"8","key":"3057_CR62","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1007\/s40265-022-01726-y","volume":"82","author":"D Menon","year":"2022","unstructured":"Menon D, Bril V. Pharmacotherapy of generalized myasthenia gravis with special emphasis on newer biologicals. Drugs. 2022;82(8):865\u201387. https:\/\/doi.org\/10.1007\/s40265-022-01726-y.","journal-title":"Drugs"},{"key":"3057_CR63","doi-asserted-by":"publisher","first-page":"886625","DOI":"10.3389\/fneur.2022.886625","volume":"13","author":"HJ Kaminski","year":"2022","unstructured":"Kaminski HJ, Denk J. Corticosteroid treatment-resistance in myasthenia gravis. Front Neurol. 2022;13:886625. https:\/\/doi.org\/10.3389\/fneur.2022.886625.","journal-title":"Front Neurol"},{"issue":"10","key":"3057_CR64","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1007\/s00018-012-0970-0","volume":"69","author":"JJ Goronzy","year":"2012","unstructured":"Goronzy JJ, Weyand CM. Immune aging and autoimmunity. Cell Mol Life Sci. 2012;69(10):1615\u201323. https:\/\/doi.org\/10.1007\/s00018-012-0970-0.","journal-title":"Cell Mol Life Sci"}],"container-title":["European Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-025-03057-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40001-025-03057-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-025-03057-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T02:44:08Z","timestamp":1755657848000},"score":1,"resource":{"primary":{"URL":"https:\/\/eurjmedres.biomedcentral.com\/articles\/10.1186\/s40001-025-03057-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,20]]},"references-count":64,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3057"],"URL":"https:\/\/doi.org\/10.1186\/s40001-025-03057-6","relation":{},"ISSN":["2047-783X"],"issn-type":[{"value":"2047-783X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,20]]},"assertion":[{"value":"1 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Since no participants have been recruited for this study, it was not subject to institutional ethical committee review. It complies with the journal\u2019s ethical requirements.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics for approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"775"}}